Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Pierre Fabre Medicament patents


Recent patent applications related to Pierre Fabre Medicament. Pierre Fabre Medicament is listed as an Agent/Assignee. Note: Pierre Fabre Medicament may have other listings under different names/spellings. We're not affiliated with Pierre Fabre Medicament, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pierre Fabre Medicament-related inventors


Gardenia extract for colouring the skin

The present invention relates to the use of a cosmetic composition intended for colouring the skin, said cosmetic composition including, as an active principle, an aqueous extract of gardenia.. . ... Pierre Fabre Medicament

Antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. ... Pierre Fabre Medicament

Derivatives of dolastatin 10 and auristatins

The present invention concerns a compound of following formula (i): where: —r1 is h or oh, —r2 is a (c1-c6)alkyl, cooh, coo—((c1-c6)alkyl) or thiazolyl group, —r3 is h or a (c1-c6)alkyl group, and —r4 is: ▪a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among oh and nr5r6, ▪—(ch2ch2x1)(ch2ch2x2)a2(ch2ch2x3)a3(ch2ch2x4)a4(ch2ch2x5)a5r7, ▪an aryl-(c1-c8)alkyl group substituted by one or more groups chosen from among oh and nr9r10 groups, or ▪a heterocycle-(c1-c8)alkyl group optionally substituted by one or more groups chosen from among (c1-c6)alkyl, oh and nr12r13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.. . ... Pierre Fabre Medicament

Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention and/or treatment of non-alcoholic steatohepatitis

. . The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.. . ... Pierre Fabre Medicament

Igf-1r antibody and its use for the diagnosis of cancer

The present disclosure relates to a novel antibody, in particular a monoclonal antibody, capable of binding to igf-1r, as well as the amino and nucleic acid sequences coding for said antibody.. . ... Pierre Fabre Medicament

Flavagline derivatives

The invention relates to compounds of the following general formula (i) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.. ... Pierre Fabre Medicament

Novel humanized adam17 antibody

The present disclosure relates to a novel humanized antibody capable of binding to adam17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the disclosure relates to a novel humanized antibody, or antigen-binding fragments, capable of binding to adam17 with anti-tumour activities. ... Pierre Fabre Medicament

Derivatives of macrocyclic n-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of ftl3 and jak

The present invention relates to a compound with the following formula (i): (i) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.. . ... Pierre Fabre Medicament

Derivatives of macrocyclic n-aryl-2-amino-4-aryl-pyrimidine polyethers as inhibitors of ftl3 and jak

The present invention relates to a compound with the following formula: formula (i) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.. . ... Pierre Fabre Medicament

Igf-1r antibody and its use as addressing vehicle for the treatment of cancer

The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to igf-1r, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to igf-1r and, by inducing internalization of igf-1r, being internalized into the cell. ... Pierre Fabre Medicament

Isoquinolinone derivatives useful in the treatment of cancer

The present invention relates to a compound of the following formula (i) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.. . ... Pierre Fabre Medicament

Method for treating movement disorders with befiradol

The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/ml which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.. ... Pierre Fabre Medicament

Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer

The present invention provides a novel, isolated anti-cxcr4 antibody for use in the diagnosis of cancer. In particular, the antibody of the invention recognizes monomeric and homodimeric cxcr4, but not heterodimeric cxcr4. ... Pierre Fabre Medicament

Flavagline derivatives

. . The invention relates to compounds of the following general formula (i) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.. ... Pierre Fabre Medicament

04/27/17 / #20170112943

Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (adc) comprising an antibody consisting of the trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin f derivative. ... Pierre Fabre Medicament

02/16/17 / #20170043032

Antibody-drug-conjugate and its use for the treatment of cancer

. . The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. ... Pierre Fabre Medicament

02/16/17 / #20170043031

Igf-1r antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate capable of binding igf-1r. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to igf-1r, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. ... Pierre Fabre Medicament








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pierre Fabre Medicament in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pierre Fabre Medicament with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###